Edwards Lifesciences has raised its fiscal year (FY25) guidance to between $2.56 to $2.62 per share after achieving better ...

Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended September 30, 2025. Recent Highlights. Q3 ...

Global announced one-year clinical outcomes for the DurAVR Transcatheter Heart Valve, or THV, in symptomatic severe ...

Edwards Lifesciences’ transcatheter aortic valve replacement (TAVR) system has demonstrated positive results in a long-term ...

People who underwent a minimally invasive procedure to have their heart's aortic valve replaced had similar health outcomes ...

The PARADIGM Trial builds on Anteris’ existing clinical data from 130 patients previously treated with the DurAVR® THV system, including first-time aortic stenosis cases, valve-in-valve patients, and ...

Anteris Technologies (AVR) announced the first patients have been enrolled and successfully treated in the DurAVR Transcatheter Heart Valve global ...

Minimally invasive lumbar decompression (MILD), also known as percutaneous image-guided lumbar decompression (PILD), is a minimally invasive treatment option for some people with spinal stenosis in ...

The American College of Cardiology and the American Heart Association have published a new guideline on the diagnosis and management of aortic disease, focusing on surgical intervention considerations ...

The results underscore the need to perform CT imaging when deciding between procedures in patients with aortic stenosis.

Dr Pankaj Garg explains how 4D flow cardiac MRI clarifies ‘grey zone’ aortic stenosis and visualises complex flow patterns to ...

SGLT2 inhibitors may have some disease-modifying potential for nonsevere aortic stenosis. After adjustments, patients on SGLT2 inhibitors had a significantly reduced risk of progression to severe ...